Literature DB >> 23007402

Epidermal growth factor (EGF) regulates α5β1 integrin activation state in human cancer cell lines through the p90RSK-dependent phosphorylation of filamin A.

Daniel Vial1, Paula J McKeown-Longo.   

Abstract

BACKGROUND: Regulation of integrin activation has important implications for tumor cell invasion and metastasis.
RESULTS: EGF activates ERK/p90RSK and Rho/Rho kinase signaling in A431 and DiFi colon cancer cells, leading to phosphorylation of filamin A (FLNa) and inactivation of the α5β1 integrin receptor.
CONCLUSION: EGF promotes α5β1 inactivation through the p90RSK-dependent phosphorylation of FLNa. SIGNIFICANCE: We have identified a novel EGF-dependent mechanism controlling the α5β1 integrin activation state. Cell adhesion, motility, and invasion are regulated by the ligand-binding activity of integrin receptors, transmembrane proteins that bind to the extracellular matrix. Integrins whose conformation allows for ligand binding and appropriate functional activity are said to be in an active state. Integrin activation and subsequent ligand binding are dynamically regulated by the association of cytoplasmic proteins with integrin intracellular domains. In this study, we evaluated the role of EGF in the regulation of the activation state of the α5β1 integrin receptor for fibronectin. The addition of EGF to either A431 squamous carcinoma cells or DiFi colon cancer cells resulted in loss of α5β1-dependent adhesion to fibronectin but no loss of integrin from the cell surface. EGF activated the EGF receptor/ERK/p90RSK and Rho/Rho kinase signaling pathways. Blocking either pathway inhibited EGF-mediated loss of adhesion, suggesting that they work in parallel to regulate integrin function. EGF treatment also resulted in phosphorylation of filamin A (FLNa), which binds and inactivates β1 integrins. EGF-mediated FLNa phosphorylation was completely blocked by an inhibitor of p90RSK and partially attenuated by an inhibitor of Rho kinase, suggesting that both pathways converge on FLNa to regulate integrin function. A431 clonal cell lines expressing non-phosphorylated dominant-negative FLNa were resistant to the inhibitory effects of EGF on integrin function, whereas clonal cell lines overexpressing wild-type FLNa were more sensitive to the inhibitory effect of EGF. These data suggest that EGF-dependent inactivation of α5β1 integrin is regulated through FLNa phosphorylation and cellular contractility.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23007402      PMCID: PMC3504752          DOI: 10.1074/jbc.M112.389577

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Increased filamin binding to beta-integrin cytoplasmic domains inhibits cell migration.

Authors:  D A Calderwood; A Huttenlocher; W B Kiosses; D M Rose; D G Woodside; M A Schwartz; M H Ginsberg
Journal:  Nat Cell Biol       Date:  2001-12       Impact factor: 28.824

2.  Talin binding to integrin beta tails: a final common step in integrin activation.

Authors:  Seiji Tadokoro; Sanford J Shattil; Koji Eto; Vera Tai; Robert C Liddington; Jose M de Pereda; Mark H Ginsberg; David A Calderwood
Journal:  Science       Date:  2003-10-03       Impact factor: 47.728

Review 3.  Integrins: bidirectional, allosteric signaling machines.

Authors:  Richard O Hynes
Journal:  Cell       Date:  2002-09-20       Impact factor: 41.582

4.  Integrin β1 mediates epithelial growth factor-induced invasion in human ovarian cancer cells.

Authors:  Man-Tat Lau; Wai-Kin So; Peter C K Leung
Journal:  Cancer Lett       Date:  2012-03-01       Impact factor: 8.679

5.  Consumption of EGF by A431 cells: evidence for receptor recycling.

Authors:  H Masui; L Castro; J Mendelsohn
Journal:  J Cell Biol       Date:  1993-01       Impact factor: 10.539

6.  Signaling by epidermal growth factor differentially affects integrin-mediated adhesion of tumor cells to extracellular matrix proteins.

Authors:  E Genersch; D Schuppan; R B Lichtner
Journal:  J Mol Med (Berl)       Date:  1996-10       Impact factor: 4.599

7.  Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient.

Authors:  M E Gross; M A Zorbas; Y J Danels; R Garcia; G E Gallick; M Olive; M G Brattain; B M Boman; L C Yeoman
Journal:  Cancer Res       Date:  1991-03-01       Impact factor: 12.701

8.  Ribosomal S6 kinase (RSK) regulates phosphorylation of filamin A on an important regulatory site.

Authors:  Michele S Woo; Yasutaka Ohta; Isaac Rabinovitz; Thomas P Stossel; John Blenis
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

9.  Role of β4 integrin phosphorylation in human invasive squamous cell carcinoma: regulation of hemidesmosome stability modulates cell migration.

Authors:  Trinayan Kashyap; Emily Germain; Michael Roche; Stephen Lyle; Isaac Rabinovitz
Journal:  Lab Invest       Date:  2011-07-18       Impact factor: 5.662

10.  Interaction of the 70,000-mol-wt amino-terminal fragment of fibronectin with the matrix-assembly receptor of fibroblasts.

Authors:  P J McKeown-Longo; D F Mosher
Journal:  J Cell Biol       Date:  1985-02       Impact factor: 10.539

View more
  19 in total

1.  Integrin bondage: filamin takes control.

Authors:  Nicola De Franceschi; Johanna Ivaska
Journal:  Nat Struct Mol Biol       Date:  2015-05       Impact factor: 15.369

2.  Regioselective Synthesis of a C-4'' Carbamate,C-6'' n-Pr Substituted Cyclitol Analogue of SL0101.

Authors:  Yu Li; Zachary M Sandusky; Rajender Vemula; Qi Zhang; Bulan Wu; Shinji Fukuda; Mingzong Li; Deborah A Lannigan; George A O'Doherty
Journal:  Org Lett       Date:  2020-02-03       Impact factor: 6.005

3.  New cancer suppressor gene for colorectal adenocarcinoma: filamin A.

Authors:  Zi-Qiang Tian; Jian-Wei Shi; Xiao-Ran Wang; Zhong Li; Gui-Ying Wang
Journal:  World J Gastroenterol       Date:  2015-02-21       Impact factor: 5.742

4.  Integrins promote cytokinesis through the RSK signaling axis.

Authors:  Shomita S Mathew; Bethsaida Nieves; Sharon Sequeira; Savitha Sambandamoorthy; Kevin Pumiglia; Melinda Larsen; Susan E Laflamme
Journal:  J Cell Sci       Date:  2013-11-27       Impact factor: 5.285

Review 5.  RSK isoforms in cancer cell invasion and metastasis.

Authors:  Florian J Sulzmaier; Joe W Ramos
Journal:  Cancer Res       Date:  2013-10-04       Impact factor: 12.701

6.  Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.

Authors:  Katarzyna A Ludwik; J Preston Campbell; Mingzong Li; Yu Li; Zachary M Sandusky; Lejla Pasic; Miranda E Sowder; David R Brenin; Jennifer A Pietenpol; George A O'Doherty; Deborah A Lannigan
Journal:  Mol Cancer Ther       Date:  2016-08-15       Impact factor: 6.261

7.  FLNA promotes chemoresistance of colorectal cancer through inducing epithelial-mesenchymal transition and smad2 signaling pathway.

Authors:  Mengmeng Cheng; Yannan Jiang; Han Yang; Dongyao Zhao; Longyu Li; Xinyu Liu
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

8.  Role of EGFR expression levels in the regulation of integrin function by EGF.

Authors:  Daniel Vial; Paula J McKeown-Longo
Journal:  Mol Carcinog       Date:  2015-06-04       Impact factor: 4.784

9.  The affinity of RSK for cylitol analogues of SL0101 is critically dependent on the B-ring C-4'-hydroxy.

Authors:  Yu Li; Pedro Seber; Eric B Wright; Sharia Yasmin; Deborah A Lannigan; George A O'Doherty
Journal:  Chem Commun (Camb)       Date:  2020-03-10       Impact factor: 6.222

Review 10.  The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance.

Authors:  Ryan Cronin; Greg N Brooke; Filippo Prischi
Journal:  Oncogene       Date:  2021-05-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.